NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
Clinical Trials
10 trialsNCT02045017 2021-08-27
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
Phase 2 Completed
NCT01337752 2020-12-17
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Novartis
Phase 2 Completed
NCT01447914 2019-08-28
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01270932 2017-12-29
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
University Health Network, Toronto
Phase 2 Completed
NCT00721734 2017-05-02
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Amgen
Phase 2 Completed
NCT00779922 2016-10-11
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Poitiers University Hospital
Phase 2 Completed
NCT01599013 2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2 Completed
NCT01084837 2015-09-17
RENVEL
PETHEMA Foundation
Phase 2 Completed
NCT00401804 2013-01-24
Bortezomib-Dexamethasone-Doxorubicin-Study
Austrian Forum Against Cancer
Phase 2 Completed